Shire PLC’s (SHPG) Overweight Rating Reaffirmed at JPMorgan Chase & Co.
SHPG has been the subject of a number of other reports. Goldman Sachs Group Inc. restated a buy rating on shares of Shire PLC in a research note on Tuesday, June 28th. HSBC downgraded Shire PLC from a buy rating to a hold rating in a research note on Monday, September 26th. Piper Jaffray Cos. set a $201.00 price objective on Shire PLC and gave the stock a hold rating in a research note on Saturday, October 1st. Shore Capital restated a buy rating on shares of Shire PLC in a research note on Saturday, August 13th. Finally, Jefferies Group restated a buy rating and set a $262.00 price objective on shares of Shire PLC in a research note on Tuesday, September 20th. Five equities research analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $228.15.
Shares of Shire PLC (NASDAQ:SHPG) traded up 2.47% on Monday, hitting $190.37. The stock had a trading volume of 252,218 shares. Shire PLC has a 12-month low of $147.60 and a 12-month high of $231.32. The firm has a market cap of $56.70 billion, a P/E ratio of 39.56 and a beta of 1.16. The company’s 50-day moving average price is $194.54 and its 200 day moving average price is $188.15.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.03 by $0.35. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The business earned $2.43 million during the quarter, compared to the consensus estimate of $2.28 billion. During the same period in the previous year, the business earned $2.63 EPS. The business’s quarterly revenue was up 55.9% on a year-over-year basis. On average, equities research analysts forecast that Shire PLC will post $12.92 earnings per share for the current fiscal year.
The business also recently declared a dividend, which was paid on Friday, October 7th. Stockholders of record on Friday, September 9th were paid a dividend of $0.139 per share. The ex-dividend date of this dividend was Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is presently 15.63%.
Several hedge funds have recently added to or reduced their stakes in SHPG. Canal Insurance CO bought a new stake in Shire PLC during the second quarter valued at about $102,000. FTB Advisors Inc. increased its stake in Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 18 shares during the period. Duncker Streett & Co. Inc. acquired a new stake in shares of Shire PLC during the second quarter valued at $111,000. Quadrant Capital Group LLC increased its stake in shares of Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 372 shares during the last quarter. Finally, Ropes Wealth Advisors LLC acquired a new stake in shares of Shire PLC during the second quarter valued at $114,000. Institutional investors own 24.30% of the company’s stock.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.